INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)-Final overall and subgroup results.

MLA

Strickland A., et al. INTEGRATE: A Randomized, Phase II, Double-Blind, Placebo-Controlled Study of Regorafenib in Refractory Advanced Oesophagogastric Cancer (AOGC): A Study by the Australasian Gastrointestinal Trials Group (AGITG)-Final Overall and Subgroup Results. 2015. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305130729&authtype=sso&custid=ns315887.

APA

Strickland A., O’Callaghan C.J., Tebbutt N.C., Rha S.Y., Lee J., Cho J.Y., Lipton L.R., Burnell M.J., Alcindor T., Kim J.W., Yip S., Simes J., Zalcberg J.R., Goldstein D., Pavlakis N., Sjoquist K.M., Tsobanis E., Martin A.J., Kang Y.-K., & Bang Y.-J. (2015). INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)-Final overall and subgroup results.

Chicago

Strickland A., O’Callaghan C.J., Tebbutt N.C., Rha S.Y., Lee J., Cho J.Y., Lipton L.R., et al. 2015. “INTEGRATE: A Randomized, Phase II, Double-Blind, Placebo-Controlled Study of Regorafenib in Refractory Advanced Oesophagogastric Cancer (AOGC): A Study by the Australasian Gastrointestinal Trials Group (AGITG)-Final Overall and Subgroup Results.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305130729&authtype=sso&custid=ns315887.